PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma

Sponsor
Shanghai Jiao Tong University School of Medicine
Study ID
NCT07641010
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
6 Years - 18 Years
Healthy Volunteers
Not accepted

Interventions

  • PD-1+JAK1i — DRUG
    PD-1 inhibitor: 3 mg/kg, IV, D1, 22; JAK1i: 4mg/m2, PO, QD, D1-35;
  • PD-1 — DRUG
    PD-1 inhibitor: 3 mg/kg, IV, D1, 22;

Study Details

A prospective, multicenter, randomized controlled clinical study of camrelizumab in combination with ivarmacitinib as first-line treatment for pediatric classical Hodgkin lymphoma

Key Dates

First listed
Jun 11, 2026
Start date
Jun 30, 2026
Status verified
Jun 2026
Primary completion
Sep 30, 2028
Completion
Sep 30, 2030

Study Design

Enrollment
112 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: PD-1+JAK1i
    PD-1+JAK1i (+AVD)
  • Active Comparator: PD-1
    PD-1 (+AVD)

Primary Outcome Measure

Complete Metabolic Response，CMR [ Time Frame: Up to 7 weeks（After the end of the 1st cycle PD-1 ± JAKi treatment period） ]

Central Contacts

Related Studies